Research
Hormonal
There is a strong correlation between online search trends and prescriptions for semaglutide (Wegovy) with a correlation coefficient of r = 0.97.
Monitoring online search trends can provide insights into public interest in obesity medications.
StrongSupportsmedium confidence
The strongest correlations between prescriptions and search volumes were observed for semaglutide (Wegovy; r = 0.97) and tirzepatide (Zepbound; r = 0.90).
Why this rating
Based on the analysis of search and prescription data.
Source
Longitudinal Analysis of Obesity Drug Use and Public Awareness
Philipp Berning et al. · JAMA Network Open · 2025
DOI 10.1001/jamanetworkopen.2024.57232
cross-sectionalCited 57×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →